Boston Scientific Acquires Penumbra for $14.5 Billion in Landmark Vascular Expansion Move

On January 15, 2026, Boston Scientific announced that it had reached a final agreement to acquire Penumbra, a manufacturer of devices for the treatment of cardiovascular and neurovascular diseases, at an enterprise value of approximately $14.5 billion (approximately RMB101 billion yuan）。The transaction is expected to be completed within this year, subject to approval by Penumbra shareholders and the satisfaction of relevant closing conditions.

This transaction isBoston Scientific's Second Acquisition Announced This Week, thisThe company has previously acquired Valencia Technologies, continuously strengtheningIts layout in the cardiovascular field.

01

Penumbra is headquartered in Alameda, California.，The company isAdam Elsesser(Ph.D. in Law from Stanford University, former law firm partner) andArani Bose(M.D. from Stanford University, Professor of Radiology at New York University) co-founded,2015listed on the NYSE in [year], as of2021Year9Monthly Market Cap Exceeds99100 million USD,2022Year6Monthly market cap exceeds50billion, becoming the global leader in thrombectomy aspiration. In 2025, Penumbra’s annual revenue is projected to reach approximately $1.4 billion, representing a year-over-year growth of about 17.3%–17.5%.

The company primarily develops treatments for moderateminimally invasive interventional devices for conditions such as stroke, pulmonary embolism, and deep vein thrombosis, with a product portfolio including:

• Neurovascular Products:Catheter systems for vascular access, stroke revascularization, and neuroembolization;

• Vascular Thrombectomy System:such as the Lightning Bolt and Lightning Flash computer-assisted vacuum thrombectomy (CAVT) systems;

• Peripheral Embolization System:For controlling bleeding or sealing blood vessels.

Boston Scientific Chairman and CEO Mike Mahoney stated, “Penumbra has a strong product portfolio and team,”This acquisition will help us rapidly enter high-growth segments in the vascular space and expand our global patient reach.”PenumbraFounder & CEOAdam Elsesser pointed out that both parties will jointly promote innovation in the treatment of complex diseases, continuing Penumbra’s clinical mission.

Boston Scientific plans to finance approximately $11 billion in cash and new debt to pay for the cash portion of the transaction. The acquisition is expected to be slightly dilutive to adjusted earnings per share (approximately 6–8 cents) in the first year post-closing, before gradually becoming accretive thereafter.

BTIG Maintains “Buy” Rating on Boston Scientific, Citing Expansion into High-Growth Areas

Analysts pointed out that after Stryker acquired Inari Medical in 2025, Penumbra, as a scarce target in the field of vascular intervention,Its unique products, market position, and growth potential have been validated. The Zimmermann team further stated,This acquisition enables Boston Scientific to achieve synergies with TCAR products in the neurovascular space, reinforcing its competitive advantages in structural heart disease and peripheral interventions.